Iconic Therapeutics

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

Iconic Therapeutics headquartered in United States, North America, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $11.9B in funding across 144 round(s). With a team of 11-50 employees, Iconic Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Iconic Therapeutics, raised $2.5M. Discover more about their projects, partnerships, and impact on our platform.